Study guide

4.5 Harm Reduction Strategies: Naloxone, Fentanyl Test Strips & Syringe Services

Certified Addictions Registered Nurse CARN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 CARN Exam Overview, Eligibility & Requirements 1.2 How to Use This Study Guide & Preparation Strategy

2 Chapter 2: Assessment & Screening

2.1 DSM-5-TR Substance Use Disorder Diagnostic Criteria & Severity Classification 2.2 Standardized Screening Tools: AUDIT, DAST-10, CAGE, CRAFFT & ASSIST 2.3 Withdrawal Severity Rating Scales: CIWA-Ar & COWS 2.4 Neonatal & Special Population Assessment: Finnegan, Eat-Sleep-Console & Life Stages 2.5 Assessment of Co-Occurring Psychiatric & Medical Disorders

3 Chapter 3: Planning & Intervention

3.1 ASAM Criteria & Continuum of Placement Care 3.2 Motivational Interviewing (OARS) & Transtheoretical Stages of Change 3.3 Trauma-Informed Care Principles & Addictions Nursing Practice 3.4 Family Dynamics, Codependency, CRAFT Model & Family Support Systems 3.5 Nursing Diagnosis, Outcome Identification & Individualized Addictions Care Planning

4 Chapter 4: Clinical Management & Pharmacotherapy

4.1 Alcohol Withdrawal Syndrome Management & Complication Prevention 4.2 Opioid Withdrawal Management & Symptom-Triggered Protocols 4.3 Medications for Opioid Use Disorder (MOUD: Methadone, Buprenorphine & Extended-Release Naltrexone) 4.4 Pharmacotherapy for Alcohol & Nicotine Use Disorders 4.5 Harm Reduction Strategies: Naloxone, Fentanyl Test Strips & Syringe Services 4.6 Pain Management in Patients with Substance Use Disorders

5 Chapter 5: Substance-Specific Disorders, Prevention & Patient Education

5.1 Stimulant Use Disorders: Cocaine, Amphetamines & Caffeine 5.2 Sedative, Hypnotic, Anxiolytic & Gabapentinoid Misuse 5.3 Cannabis & Hallucinogen Use Disorders 5.4 Tobacco Use Disorder, Vaping & Cessation Interventions 5.5 Prevention, Brief Intervention, Patient Education & Behavioral Addictions

6 Chapter 6: Evaluation, Recovery & Continuing Care

6.1 Relapse Prevention Models: Marlatt's Model, Urge Surfing & High-Risk Situations 6.2 Mutual-Help Groups & Peer Recovery Support: 12-Step, SMART Recovery & Peer Specialists 6.3 Recovery Capital, Social Determinants of Health & Holistic Wellness 6.4 Transitions of Care, Discharge Planning & Long-Term Recovery Management

7 Chapter 7: Professional Role, Ethics & Legal Issues

7.1 ANA/IntNSA Scope & Standards of Addictions Nursing Practice 7.2 Confidentiality Laws: 42 CFR Part 2 vs. HIPAA & 2024 Alignment Updates 7.3 Legal & Ethical Issues, Stigma Reduction & Person-First Language

4.5 Harm Reduction Strategies: Naloxone, Fentanyl Test Strips & Syringe Services

Key Takeaways Explain This Topic AI

Naloxone is a high-affinity competitive mu-opioid receptor antagonist that rapidly reverses opioid-induced respiratory depression; standard community formulations include 4 mg intranasal spray and 0.4–2 mg IM/IV injection.

The elimination half-life of naloxone (30–90 minutes) is substantially shorter than long-acting opioids (e.g., methadone 24–36 hours), creating a high risk of renarcotization (re-emergence of respiratory arrest) requiring clinical monitoring for at least 2–4 hours.

Fentanyl test strips (FTS) detect synthetic fentanyl and fentanyl analogues in dissolved drug samples prior to consumption, empowering individuals to adopt risk-reduction behaviors.

Syringe Services Programs (SSPs) reduce HIV and Hepatitis C transmission by over 50%, provide safe disposal of contaminated sharp waste, and serve as a primary gateway to substance use treatment and medical care.

Harm reduction is a pragmatic, evidence-based public health framework that prioritizes reducing adverse health and social consequences of drug use without making total abstinence a mandatory prerequisite for receiving care.

Last updated: August 2026

  • Harm Reduction Strategies: Naloxone, Fentanyl Test Strips & Syringe Services
  • Foundations & Ethics of Harm Reduction

Harm reduction is a pragmatic, evidence-based public health paradigm and ethical clinical framework dedicated to reducing the negative health, social, and legal consequences associated with psychoactive substance use. Unlike traditional zero-tolerance models that demand immediate abstinence as a condition for receiving healthcare services, harm reduction "meets people where they are" without judgment or coercion.

Core principles for the Certified Addictions Registered Nurse (CARN) include:

Accepting that licit and illicit drug use is part of human society and focusing on minimizing harm rather than punishing behavior.

Establishing low-barrier access to life-saving interventions (naloxone, sterile injection supplies, drug checking).

Utilizing non-stigmatizing, person-first language (e.g., "person who uses drugs" rather than "addict" or "junkie").

Recognizing human rights, individual autonomy, and self-determination in healthcare choices.

Naloxone Administration & Overdose Reversal Protocols

Naloxone (Narcan, Kloxxado) is a pure, high-affinity competitive mu-opioid receptor antagonist . It rapidly displaces exogenous opioids from mu-receptors, reversing opioid-induced central nervous system depression and restoring spontaneous respiration within 2 to 3 minutes .

Clinical Manifestations of Opioid Overdose (The Opioid Triad)

Respiratory Depression: Respiratory rate <8–10 breaths/min, shallow breathing, or apnea.

Stupor / Unconsciousness: Unresponsive to noxious tactile or verbal stimuli.

Miosis: Constricted, pin-point pupils (note: may be dilated if severe hypoxic brain injury has occurred or if co-ingested with sympathomimetics).

Additional physical signs include central cyanosis (blue/ashen lips, fingernails) and the characteristic "death rattle" (gurgling, snoring sounds indicating partial airway obstruction).

Community & Healthcare Administration Steps

Intranasal (IN) Spray (Narcan 4 mg / Kloxxado 8 mg): Peel blister pack, insert nozzle tip into one nostril, and press plunger firmly until it clicks. Do NOT test or prime the device prior to use.

Intramuscular (IM) / Intravenous (IV) Injection (0.4 mg to 2 mg): Inject into outer thigh or upper arm.

Immediate Post-Administration Interventions:

Call Emergency Medical Services (EMS / 911).

Administer rescue breathing (1 breath every 5 seconds) or chest compressions if pulse absent.

If no response after 2 to 3 minutes , administer a second dose of naloxone in the opposite nostril.

Place patient in the Recovery Position (side-lying with top knee bent) to prevent aspiration if vomiting occurs upon reversal. Opioid Overdose Emergency Protocol:

  • Unresponsive + Apneic/Bradypneic --> Call 911 --> Administer Intranasal Naloxone (4mg)
  • -> Provide Rescue Breathing (1 breath / 5 sec)
  • -> No response in 2-3 min? --> Administer 2nd Naloxone Dose
  • -> Place in Recovery Position
  • Renarcotization Surveillance & Post-Overdose Nursing Care
  • The Danger of Renarcotization

Naloxone has a relatively short elimination half-life of 30 to 90 minutes . In contrast, many opioids possess significantly longer duration of action (e.g., sustained-release morphine, oxycodone CR, methadone [half-life 24–36h], or chronic adipose-stored fentanyl).

As naloxone molecules dissociate from mu-receptors and are metabolized, remaining un-metabolized opioid molecules re-bind to mu-receptors, precipitating secondary respiratory arrest—a phenomenon known as renarcotization .

CRITICAL NURSING MONITORED PROTOCOL: Every patient who receives naloxone for opioid overdose reversal must be monitored in a clinical setting for a MINIMUM of 2 to 4 hours (and longer for long-acting opioids like methadone). Monitor continuous pulse oximetry, respiratory rate, and level of consciousness.

Managing Acute Opioid Antagonist Withdrawal

Naloxone reversal causes immediate severe opioid withdrawal (agitation, vomiting, tachycardia, diaphoresis). The nurse must provide calm reassurance, maintain airway protection against aspiration, and prevent patient departure prior to completing the observation window.

  • Drug Checking Technology: Fentanyl & Xylazine Test Strips
  • Fentanyl Test Strips (FTS)

Fentanyl test strips are immunoassay test strips capable of detecting the presence of fentanyl and illicit fentanyl analogues in drug samples (powders, pills, injectables) prior to consumption.

Patient Education / Testing Protocol: Dissolve a small drug sample (approx. 10 mg or size of a grain of rice) in water. Dip strip for 15 seconds, lay flat, and read results at 2 minutes.

Interpretation: One line = POSITIVE for fentanyl; Two lines = NEGATIVE for fentanyl. (Crucial teaching point: opposite of home pregnancy tests).

Dilution Warnings: Using insufficient water to dissolve dense pill residues can cause false-positive readings due to high binder concentration.

Xylazine ("Tranq") Adulteration

Xylazine is a non-opioid alpha-2 adrenergic agonist (veterinary sedative) increasingly found as an adulterant in illicit fentanyl supplies.

Clinical Impact: Xylazine worsens sedation and hypotension. Naloxone DOES NOT reverse xylazine because xylazine does not bind to mu-opioid receptors. However, naloxone MUST still be given in all suspected overdoses to reverse the underlying fentanyl component.

Necrotizing Skin Lesions: Xylazine causes severe, painful necrotic skin ulcers at both injection and non-injection sites due to peripheral vasoconstriction, requiring aggressive nursing wound care.

Syringe Services Programs (SSPs) & Disease Prevention

Syringe Services Programs (SSPs) —also known as Needle Exchange Programs—are comprehensive community-based public health programs.

Evidence-Based Benefits

Infection Reduction: Reduces transmission of HIV, Hepatitis B, and Hepatitis C by >50% .

Treatment Referral: Participants in SSPs are 5 times more likely to enter drug treatment programs and 3 times more likely to stop using drugs than non-participants.

Public Safety: Provides safe disposal containers for used sharps, reducing needle-stick injuries to law enforcement and first responders.

Comprehensive Care Hub: Delivers wound care, vaccinations (Hepatitis A/B), STI screening, naloxone distribution, and social service navigation.

Harm Reduction Nursing Protocol Matrix

Intervention Clinical Purpose Essential Patient Education

Intranasal Naloxone Rapid reversal of fatal opioid respiratory arrest Keep accessible; educate family/peers; call 911; stay with patient post-dosing

Fentanyl Test Strips Pre-consumption detection of synthetic opioids Test every batch; 1 line = positive; use less, avoid solo use, keep naloxone ready

Sterile Injection Equipment Prevents HIV, HCV, endocarditis, and abscesses Use new sterile needle/cooker/filter for every injection; clean skin with alcohol

Xylazine Test Strips Detects non-opioid adulterant causing skin necrosis Administer naloxone for overdose; seek specialized wound care for non-healing ulcers

Loading diagram... Opioid Overdose Response & Renarcotization Monitoring Protocol